Ablynx Receives Milestone Payment as Collaborator Receives IND Approval for a Nanobody in Oncology
Ablynx has announced that it has received a €400,000 milestone payment from its collaboration with Novartis.
The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase 1 clinical trial for a Nanobody® licensed to Novartis.
This is the first development candidate emerging from the licensing agreement between Ablynx and Novartis.
Ablynx and Novartis entered into a commercial licensing agreement in July 2010, under which Novartis obtained licenses to develop and commercialize Nanobodies against two targets (including this one for which an IND has been approved), which originated from the research agreement between the parties, entered into in 2005.
Since July 2010, Novartis has full responsibility for the continued progress of both programmes and Ablynx is eligible to receive development-based milestone payments and royalties on sales following commercialization of the products.
Dr Edwin Moses, CEO and Chairman of Ablynx, commented: “We are excited that Novartis has obtained IND approval and that they will bring this first Nanobody into clinical development in an oncology setting. This development candidate demonstrates the power of the Nanobody platform in addressing complex target classes that are challenging to address with conventional antibodies.”